Does Erlotinib Restore Chemosensitivity to Chemotherapy in Pancreatic Cancer? A Retrospective Analysis
Background Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, in combination with
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Background Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, in combination with
Background Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, in combination with
Background There is literature showing an association between obesity and outcomes of
Background The effects of adjuvant radiation therapy on pancreatic cancer outcomes after
Introduction:Pancreatic adenocarcinoma is a devastating malignancy, associated with a grim prognosis
Pancreatic cancer is a very aggressive disease and survival remains dismal even
Pancreatic cancer has the worst survival of any solid tumor. Overall, pancreatic
Background Pancreatectomy offers only potential for cure but is only possible in
Pancreatic enzyme replacement therapy is safe and effective at treating pancreatic exocrine
Background Carcinoma of unknown primary represents a therapeutic challenge in oncological practice
The prognosis for pancreatic cancer remains poor and curative treatment currently involves
Pancreatic Cancer is the fourth cause of cancer-related deaths in the
Kidney disease is a complication that is observed in 10%?30% of
Pancreatic cancer is an aggressive and devastating cancer that continues to have
Despite decades of research, pancreatic cancer remains essentially incurable for patients with
Pancreatic adenocarcinoma is the 10th most common malignancy in the United States
In the field of treatment of pancreatic cancer, there has been significant
FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely
Metastatic pancreatic cancer continues to be a difficult disease to treat because
Pancreatic cancer is the fourth leading cause of cancer-related deaths in
Pancreatic cancer is ranked as the fourth leading cause of cancer-related
Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) is increasingly used for
For authors and organisers
Find the right journal for your paper and submit your manuscript.